中国人群HIV1 CD8 T细胞应答免疫显性表位鉴定与检

2019-05-16 15:14 来源:互联网
中国人群特异性HIV-1 CD8 + T细胞的免疫应答
筛选和鉴定优势表位
研究生:说真的
主题:内科(传染病)
单位:第四军医大学,唐都医院,传染病科
讲师:孙永涛教授
导师:
项目资金:美国NIH合作项目UU No 1-AI-30024
关键词:人类免疫缺陷病毒1型;获得性免疫缺陷综合征CD8 + T.
淋巴细胞细胞毒性T淋巴细胞。表位;功能
中国第四军医大学人民解放军。
2009年5月
第四军医大学博士论文。
目录
缩写列表????????????????????????????????????????????????????????????????????????????????????????????????????
中文摘要本中文摘要本中文摘要中文摘要本中文摘要中文摘要中文摘要本中文摘要中文摘要?·····················4
摘要..............................................................................................................................................................................................................................................................................................................???????????????????????????????????????????????????????????? 8
介绍·························································································
文献综述?·················································????????????????????????????
1艾滋病流行状况································································
1
1世界范围的艾滋病流行情况???????????????????????????························································
1
2中国艾滋病流行·······································································································15
2HIV-1的发病机理本发明的发病机理是由2HIV-1的发病机制实现的。??????????????????????????????????????????????????日期和时间15
2
1HIV-1形式??????????????????????????????????? ...............................................................······································16
2
2 HIV-1基因组················································································
2
3 HIV-1蛋白质代码·················································································································
3 HIV-1特异性细胞毒性T淋巴细胞在HIV-1感染中的作用........................................... 18
3
1 CTL细胞免疫应答············································································....................................................................................................................................................................................................................................................... 18
3
1
1 MHC-I限制免疫优势?